Fluoxetine, a common antidepressant, inhibits the SARS-CoV-2 coronavirus in cell cultures and in preparations from human lung tissue. This was demonstrated by researchers at Julius-Maximilians-Universität (JMU) Würzburg in the summer of 2020. However, the mechanism of this inhibition was utterly unclear, so the teams continued their research. To this end, they developed the molecule AKS466,
Cedars-Sinai Researchers Find 56% Were Unaware They Were Infected With Omicron Variant of SARS-CoV-2 The majority of people who were likely infected with the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, didn’t know they had the virus, according to a new study from Cedars-Sinai investigators. The findings are published in JAMA Network Open. “More
Findings from a new study at the Marshall University Joan C. Edwards School of Medicine show that a thymidine phosphorylase (TYMP) inhibitor could help slow thrombosis in COVID-19 patients. Expression of TYMP, the gene that plays an important role in platelet activation, thrombosis and inflammation, is significantly increased in COVID-19 patients. The increase of TYMP
Hospitalized adult COVID-19 patients before and after SARS-CoV-2 vaccine availability had significantly higher odds of venous—but not arterial—thromboembolism than those hospitalized for influenza before the pandemic, finds a study published today in JAMA. A team led by University of Pennsylvania researchers retrospectively studied rates of venous thromboembolism (blood clot in a vein) and arterial thromboembolism (blood clot in
The results of a retrospective cohort study from the TriNetX US collaborative networks are published in eClinicalMedicine Background The long-term cardiovascular outcomes in COVID-19 survivors remain largely unclear. The aim of this study was to investigate the long-term cardiovascular outcomes in COVID-19 survivors. Methods This study used the data from the US Collaborative Network in
Findings could lead to new strategies to treat COVID-19 infections A team led by UT Southwestern researchers has identified how SARS-CoV-2, the virus that causes COVID-19, builds a structure called the RNA cap that’s critical for successful viral replication. The finding, published in Nature, could lead to new strategies to attack COVID-19, which has sickened nearly 600
A team of researchers affiliated with several institutions in Brazil has found evidence of the SARS-CoV-2 virus infecting astrocyte cells in the human brain. In their paper published in Proceedings of the National Academy of Sciences, the group describes their study of the brains of people who had died from COVID-19 and what was found. From
The Association for the Advancement of Blood and Biotherapies (AABB) has released clinical practice guidelines for the appropriate use of COVID-19 convalescent plasma (CCP) in hospital and outpatient settings. Based on two living systematic reviews of randomized controlled trials (RCTs), the guidelines provide five specific recommendations for treating patients with COVID-19 and suggest that CCP
The US Government is committed to helping people across America affected by Long COVID. In April, President Joe Biden issued a Memorandum on Addressing the Long-Term Effects of COVID-19, which called for the creation of two reports. Within 120 days, the U.S. Department of Health and Human Services (HHS), leading a whole-of-government response, developed two reports that
A protein that could be an early indicator of severe COVID-19 has been identified and described by scientists at the University of Aberdeen. Patients who get seriously ill following a COVID-19 infection frequently show evidence of a severe form of lung disease and in around 30% of patients blood clots are evident. Blood clots arise
